{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:33:02Z","timestamp":1787682782490,"version":"build-2784847793"},"reference-count":191,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41584-020-0458-5","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T10:04:17Z","timestamp":1596621857000},"page":"481-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-6458","authenticated-orcid":false,"given":"Dario","family":"Camellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Matteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-0668","authenticated-orcid":false,"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"458_CR1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","volume":"58","author":"RC Lawrence","year":"2008","unstructured":"Lawrence, R. C. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58, 26\u201335 (2008).","journal-title":"Arthritis Rheum."},{"key":"458_CR2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2017.04.001","volume":"47","author":"CS Crowson","year":"2017","unstructured":"Crowson, C. S. & Matteson, E. L. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin. Arthritis Rheum. 47, 253\u2013256 (2017).","journal-title":"Semin. Arthritis Rheum."},{"key":"458_CR3","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit, F., Dejaco, C., Matteson, E. L. & Dasgupta, B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315, 2442\u20132458 (2016).","journal-title":"JAMA"},{"key":"458_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","volume":"41","author":"MC Cid","year":"1998","unstructured":"Cid, M. C. et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 41, 26\u201332 (1998).","journal-title":"Arthritis Rheum."},{"key":"458_CR5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-9343(01)00770-7","volume":"111","author":"E Liozon","year":"2001","unstructured":"Liozon, E. et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am. J. Med. 111, 211\u2013217 (2001).","journal-title":"Am. J. Med."},{"key":"458_CR6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","volume":"48","author":"C Salvarani","year":"2008","unstructured":"Salvarani, C. et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology 48, 250\u2013253 (2008).","journal-title":"Rheumatology"},{"key":"458_CR7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9394(99)80193-7","volume":"125","author":"SS Hayreh","year":"1998","unstructured":"Hayreh, S. S., Podhajsky, P. A. & Zimmerman, B. Occult giant cell arteritis: ocular manifestations. Am. J. Ophthalmol. 125, 521\u2013526 (1998).","journal-title":"Am. J. Ophthalmol."},{"key":"458_CR8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-83-6-806","volume":"83","author":"RG Klein","year":"1975","unstructured":"Klein, R. G., Hunder, G. G., Stanson, A. W. & Sheps, S. G. Large artery involvement in giant cell (temporal) arteritis. Ann. Intern. Med. 83, 806\u2013812 (1975).","journal-title":"Ann. Intern. Med."},{"key":"458_CR9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","volume":"42","author":"A Brack","year":"1999","unstructured":"Brack, A., Martinez-Taboada, V., Stanson, A., Goronzy, J. J. & Weyand, C. M. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 42, 311\u2013317 (1999).","journal-title":"Arthritis Rheum."},{"key":"458_CR10","first-page":"506","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco, C., Duftner, C., Buttgereit, F., Matteson, E. L. & Dasgupta, B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology 56, 506\u2013515 (2017).","journal-title":"Rheumatology"},{"key":"458_CR11","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/acr.23498","volume":"70","author":"F Muratore","year":"2018","unstructured":"Muratore, F. et al. Large-vessel dilatation in giant cell arteritis: a different subset of disease? Arthritis Care Res. 70, 1406\u20131411 (2018).","journal-title":"Arthritis Care Res."},{"key":"458_CR12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/art.1780390220","volume":"39","author":"SM Helfgott","year":"1996","unstructured":"Helfgott, S. M. & Kieval, R. I. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum. 39, 304\u2013307 (1996).","journal-title":"Arthritis Rheum."},{"key":"458_CR13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/35.11.1161","volume":"35","author":"G Myklebust","year":"1996","unstructured":"Myklebust, G. & Gran, J. T. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br. J. Rheumatol. 35, 1161\u20131168 (1996).","journal-title":"Br. J. Rheumatol."},{"key":"458_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2000.8366","volume":"30","author":"F Cantini","year":"2000","unstructured":"Cantini, F. et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin. Arthritis Rheum. 30, 17\u201324 (2000).","journal-title":"Semin. Arthritis Rheum."},{"key":"458_CR15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/rheumatology\/key431","volume":"58","author":"C Manzo","year":"2019","unstructured":"Manzo, C., Milchert, M., Natale, M. & Brzosko, M. Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis. Rheumatology 58, 921\u2013923 (2019).","journal-title":"Rheumatology"},{"key":"458_CR16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","volume":"49","author":"A Proven","year":"2003","unstructured":"Proven, A., Gabriel, S. E., Orces, C., O\u2019Fallon, W. M. & Hunder, G. G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Care Res. 49, 703\u2013708 (2003).","journal-title":"Arthritis Care Res."},{"key":"458_CR17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","volume":"55","author":"JR Curtis","year":"2006","unstructured":"Curtis, J. R. et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 55, 420\u2013426 (2006).","journal-title":"Arthritis Rheum."},{"key":"458_CR18","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","volume":"68","author":"JN Hoes","year":"2009","unstructured":"Hoes, J. N., Jacobs, J. W. G., Verstappen, S. M. M., Bijlsma, J. W. J. & Van der Heijden, G. J. M. G. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann. Rheum. Dis. 68, 1833\u20131838 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2016.05.009","volume":"46","author":"MS Broder","year":"2016","unstructured":"Broder, M. S. et al. Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin. Arthritis Rheum. 46, 246\u2013252 (2016).","journal-title":"Semin. Arthritis Rheum."},{"key":"458_CR20","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/kex459","volume":"57","author":"F Buttgereit","year":"2018","unstructured":"Buttgereit, F., Matteson, E. L., Dejaco, C. & Dasgupta, B. Prevention of glucocorticoid morbidity in giant cell arteritis. Rheumatology 57, ii11\u2013ii21 (2018).","journal-title":"Rheumatology"},{"key":"458_CR21","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/art.1780401022","volume":"40","author":"SE Gabriel","year":"1997","unstructured":"Gabriel, S. E., Sunku, J., Salvarani, C., O\u2019Fallon, W. M. & Hunder, G. G. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 40, 1873\u20131878 (1997).","journal-title":"Arthritis Rheum."},{"key":"458_CR22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3899\/jrheum.110851","volume":"39","author":"M Mazzantini","year":"2012","unstructured":"Mazzantini, M. et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J. Rheumatol. 39, 552\u2013557 (2012).","journal-title":"J. Rheumatol."},{"key":"458_CR23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317\u2013328 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 10","key":"458_CR24","first-page":"1389","volume":"71","author":"JH Stone","year":"2019","unstructured":"Stone, J. H. et al. Long-term outcome of tocilizumab for patients with giant cell arteritis: results from part 2 of a randomized controlled phase 3 trial [abstract 0808]. Arthritis Rheumatol. 71 (Suppl 10), 1389\u20131390 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"458_CR25","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally, L., Forbess, L., Hatzis, C. & Spiera, R. Brief report: a prospective open-label phase iia trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 68, 2550\u20132554 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"458_CR26","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec, V. et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann. Rheum. Dis. 75, 1506\u20131510 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR27","first-page":"S103","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil, P. et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin. Exp. Rheumatol. 33, S103\u2013S106 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"458_CR28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","volume":"55","author":"AP Diamantopoulos","year":"2016","unstructured":"Diamantopoulos, A. P., Haugeberg, G., Lindland, A. & Myklebust, G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology 55, 66\u201370 (2016).","journal-title":"Rheumatology"},{"key":"458_CR29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","volume":"41","author":"MA Gonz\u00e1lez-Gay","year":"1998","unstructured":"Gonz\u00e1lez-Gay, M. A. et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 41, 1497\u20131504 (1998).","journal-title":"Arthritis Rheum."},{"key":"458_CR30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/art.23315","volume":"59","author":"A Garc\u00eda-Mart\u00ednez","year":"2008","unstructured":"Garc\u00eda-Mart\u00ednez, A. et al. Development of aortic aneurysm\/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Care Res. 59, 422\u2013430 (2008).","journal-title":"Arthritis Care Res."},{"key":"458_CR31","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/annrheumdis-2013-203322","volume":"73","author":"A Garc\u00eda-Mart\u00ednez","year":"2014","unstructured":"Garc\u00eda-Mart\u00ednez, A. et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann. Rheum. Dis. 73, 1826\u20131832 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3109\/s10165-011-0581-x","volume":"22","author":"H Yamashita","year":"2012","unstructured":"Yamashita, H. et al. Whole-body fluorodeoxyglucose positron emission tomography\/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Mod. Rheumatol. 22, 705\u2013711 (2012).","journal-title":"Mod. Rheumatol."},{"key":"458_CR33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1529-0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W","volume":"41","author":"C Salvarani","year":"1998","unstructured":"Salvarani, C. et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 41, 1221\u20131226 (1998).","journal-title":"Arthritis Rheum."},{"key":"458_CR34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.rhu.0000231381.21179.e6","volume":"12","author":"F Ceccato","year":"2006","unstructured":"Ceccato, F. et al. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J. Clin. Rheumatol. 12, 167\u2013171 (2006).","journal-title":"J. Clin. Rheumatol."},{"key":"458_CR35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MD.0b013e318145275c","volume":"86","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2007","unstructured":"Hern\u00e1ndez-Rodr\u00edguez, J. et al. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients. Medicine 86, 233\u2013241 (2007).","journal-title":"Medicine"},{"key":"458_CR36","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3899\/jrheum.170455","volume":"45","author":"E Liozon","year":"2018","unstructured":"Liozon, E. et al. Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study. J. Rheumatol. 45, 678\u2013685 (2018).","journal-title":"J. Rheumatol."},{"key":"458_CR37","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.151063","volume":"43","author":"TA Kermani","year":"2016","unstructured":"Kermani, T. A. et al. The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis. J. Rheumatol. 43, 1078\u20131084 (2016).","journal-title":"J. Rheumatol."},{"key":"458_CR38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/rheumatology\/kex397","volume":"57","author":"TA Kermani","year":"2018","unstructured":"Kermani, T. A. et al. Evaluation of damage in giant cell arteritis. Rheumatology 57, 322\u2013328 (2018).","journal-title":"Rheumatology"},{"key":"458_CR39","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3899\/jrheum.181072","volume":"46","author":"SZ Aydin","year":"2019","unstructured":"Aydin, S. Z. et al. Update on outcome measure development in large-vessel vasculitis: report from OMERACT 2018. J. Rheumatol. 46, 1198\u20131201 (2019).","journal-title":"J. Rheumatol."},{"key":"458_CR40","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3899\/jrheum.161467","volume":"44","author":"AG Sreih","year":"2017","unstructured":"Sreih, A. G. et al. Development of a core set of outcome measures for large-vessel vasculitis: report from OMERACT 2016. J. Rheumatol. 44, 1933\u20131937 (2017).","journal-title":"J. Rheumatol."},{"key":"458_CR41","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1136\/annrheumdis-2018-214755","volume":"78","author":"L Ehlers","year":"2019","unstructured":"Ehlers, L. et al. 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Ann. Rheum. Dis. 78, 1160\u20131166 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR42","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb, B. F. & Bird, H. A. A disease activity score for polymyalgia rheumatica. Ann. Rheum. Dis. 63, 1279\u20131283 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2008.088526","volume":"68","author":"A Binard","year":"2009","unstructured":"Binard, A., Lefebvre, B., De Bandt, M., Berthelot, J.-M. & Saraux, A. Validity of the polymyalgia rheumatica activity score in primary care practice. Ann. Rheum. Dis. 68, 541\u2013545 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR44","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3899\/jrheum.161109","volume":"44","author":"SL Mackie","year":"2017","unstructured":"Mackie, S. L. et al. The OMERACT core domain set for outcome measures for clinical trials in polymyalgia rheumatica. J. Rheumatol. 44, 1515\u20131521 (2017).","journal-title":"J. Rheumatol."},{"key":"458_CR45","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3899\/jrheum.141347","volume":"42","author":"TA Kermani","year":"2015","unstructured":"Kermani, T. A. et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J. Rheumatol. 42, 1213\u20131217 (2015).","journal-title":"J. Rheumatol."},{"key":"458_CR46","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","volume":"71","author":"JH Stone","year":"2019","unstructured":"Stone, J. H. et al. Glucocorticoid dosages and acute\u2010phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab. Arthritis Rheumatol. 71, 1329\u20131338 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"458_CR47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani, C. et al. Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 53, 33\u201338 (2005).","journal-title":"Arthritis Rheum."},{"key":"458_CR48","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3899\/jrheum.131055","volume":"41","author":"EM McCarthy","year":"2014","unstructured":"McCarthy, E. M. et al. Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study. J. Rheumatol. 41, 931\u2013937 (2014).","journal-title":"J. Rheumatol."},{"key":"458_CR49","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000570","volume":"3","author":"S Prieto-Gonz\u00e1lez","year":"2017","unstructured":"Prieto-Gonz\u00e1lez, S. et al. Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open 3, e000570 (2017).","journal-title":"RMD Open"},{"key":"458_CR50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.1660","volume":"204","author":"D Foell","year":"2004","unstructured":"Foell, D. et al. Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. J. Pathol. 204, 311\u2013316 (2004).","journal-title":"J. Pathol."},{"key":"458_CR51","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/rheumatology\/kel128","volume":"45","author":"MC Cid","year":"2006","unstructured":"Cid, M. C. et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology 45, 1356\u20131363 (2006).","journal-title":"Rheumatology"},{"key":"458_CR52","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/kez034","volume":"58","author":"Y van Sleen","year":"2019","unstructured":"van Sleen, Y. et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology 58, 1383\u20131392 (2019).","journal-title":"Rheumatology"},{"key":"458_CR53","first-page":"2239","volume":"54","author":"J Inciarte-Mundo","year":"2015","unstructured":"Inciarte-Mundo, J. et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology 54, 2239\u20132243 (2015).","journal-title":"Rheumatology"},{"key":"458_CR54","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/RHU.0000000000000729","volume":"24","author":"JM Springer","year":"2018","unstructured":"Springer, J. M. et al. Serum S100 proteins as a marker of disease activity in large vessel vasculitis. J. Clin. Rheumatol. 24, 393\u2013395 (2018).","journal-title":"J. Clin. Rheumatol."},{"key":"458_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-007-9126-7","volume":"28","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Garlanda, C., Doni, A. & Bottazzi, B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J. Clin. Immunol. 28, 1\u201313 (2008).","journal-title":"J. Clin. Immunol."},{"key":"458_CR56","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/art.33411","volume":"64","author":"M Baldini","year":"2012","unstructured":"Baldini, M. et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia. Arthritis Rheum. 64, 854\u2013865 (2012).","journal-title":"Arthritis Rheum."},{"key":"458_CR57","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/rheumatology\/key158","volume":"57","author":"AD Gloor","year":"2018","unstructured":"Gloor, A. D. et al. Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis. Rheumatology 57, 1795\u20131801 (2018).","journal-title":"Rheumatology"},{"key":"458_CR58","first-page":"756","volume":"28","author":"L Pulsatelli","year":"2010","unstructured":"Pulsatelli, L. et al. Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica. Clin. Exp. Rheumatol. 28, 756\u2013758 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"458_CR59","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3389\/fimmu.2019.01981","volume":"10","author":"Y van Sleen","year":"2019","unstructured":"van Sleen, Y. et al. Leukocyte dynamics reveal a persistent myeloid dominance in giant cell arteritis and polymyalgia rheumatica. Front. Immunol. 10, 1981 (2019).","journal-title":"Front. Immunol."},{"key":"458_CR60","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/ard.48.4.307","volume":"48","author":"B Dasgupta","year":"1989","unstructured":"Dasgupta, B., Duke, O., Timms, A. M., Pitzalis, C. & Panayi, G. S. Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis. Ann. Rheum. Dis. 48, 307\u2013311 (1989).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR61","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/rheumatology\/35.7.642","volume":"35","author":"L Boiardi","year":"1996","unstructured":"Boiardi, L. et al. CD8 lymphocyte subsets in active polymyalgia rheumatica: comparison with elderly-onset and adult rheumatoid arthritis and influence of prednisone therapy. Br. J. Rheumatol. 35, 642\u2013648 (1996).","journal-title":"Br. J. Rheumatol."},{"key":"458_CR62","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/art.38625","volume":"66","author":"KSM van der Geest","year":"2014","unstructured":"van der Geest, K. S. M. et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 66, 1927\u20131938 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"458_CR63","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2016-210070","volume":"76","author":"C Miyabe","year":"2017","unstructured":"Miyabe, C. et al. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann. Rheum. Dis. 76, 898\u2013905 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR64","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","volume":"64","author":"M Samson","year":"2012","unstructured":"Samson, M. et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 64, 3788\u20133798 (2012).","journal-title":"Arthritis Rheum."},{"key":"458_CR65","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","volume":"77","author":"C Dejaco","year":"2018","unstructured":"Dejaco, C. et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann. Rheum. Dis. 77, 636\u2013643 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-017-1499-2","volume":"20","author":"A Huwart","year":"2018","unstructured":"Huwart, A. et al. Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. Arthritis Res. Ther. 20, 11 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"458_CR67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/14397595.2019.1591065","volume":"30","author":"K Kaneko","year":"2020","unstructured":"Kaneko, K., Suematsu, E., Miyamura, T. & Ishioka, H. Differences of articular and extra-articular involvement in polymyalgia rheumatica: a comparison by whole-body FDG-PET\/CT. Mod. Rheumatol. 30, 358\u2013364 (2020).","journal-title":"Mod. Rheumatol."},{"key":"458_CR68","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000598","volume":"4","author":"S Chrysidis","year":"2018","unstructured":"Chrysidis, S. et al. Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT large vessel vasculitis ultrasound working group. RMD Open 4, e000598 (2018).","journal-title":"RMD Open"},{"key":"458_CR69","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/rheumatology\/kex381","volume":"57","author":"E De Miguel","year":"2018","unstructured":"De Miguel, E. et al. Atherosclerosis as a potential pitfall in the diagnosis of giant cell arteritis. Rheumatology 57, 318\u2013321 (2018).","journal-title":"Rheumatology"},{"issue":"Suppl 2","key":"458_CR70","first-page":"181","volume":"78","author":"E Fern\u00e1ndez","year":"2019","unstructured":"Fern\u00e1ndez, E. et al. OP0210 False positives of ultrasound in giant cell arteritis. Some diseases can also have halo sign. Ann. Rheum. Dis. 78 (Suppl. 2), 181 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR71","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/rheumatology\/kez355","volume":"58","author":"WA Schmidt","year":"2019","unstructured":"Schmidt, W. A. The ultrasound halo sign of temporal arteries: is it always giant cell arteritis? Rheumatology 58, 1898\u20131899 (2019).","journal-title":"Rheumatology"},{"issue":"Suppl 2","key":"458_CR72","first-page":"817","volume":"78","author":"P Bosch","year":"2019","unstructured":"Bosch, P. et al. FRI0274 Ultrasound cut-off value for intima-media thickness of the axillary arteries in patients with chronic large-vessel giant cell arteritis. Ann. Rheum. Dis. 78 (Suppl. 2), 817 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR73","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/ard.2009.122135","volume":"69","author":"M Aschwanden","year":"2010","unstructured":"Aschwanden, M. et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. Ann. Rheum. Dis. 69, 1356\u20131359 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR74","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/rheumatology\/kex341","volume":"57","author":"S Monti","year":"2018","unstructured":"Monti, S. et al. The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. Rheumatology 57, 112\u2013119 (2018).","journal-title":"Rheumatology"},{"key":"458_CR75","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/rheumatology\/key383","volume":"58","author":"M Aschwanden","year":"2019","unstructured":"Aschwanden, M. et al. Vessel wall plasticity in large vessel giant cell arteritis: an ultrasound follow-up study. Rheumatology 58, 792\u2013797 (2019).","journal-title":"Rheumatology"},{"key":"458_CR76","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00259-018-3973-8","volume":"45","author":"RHJA Slart","year":"2018","unstructured":"Slart, R. H. J. A. et al. FDG-PET\/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur. J. Nucl. Med. Mol. Imaging 45, 1250\u20131269 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"458_CR77","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00259-018-4021-4","volume":"45","author":"BD Nielsen","year":"2018","unstructured":"Nielsen, B. D. et al. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur. J. Nucl. Med. Mol. Imaging 45, 1119\u20131128 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"458_CR78","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3899\/jrheum.170138","volume":"44","author":"AH Clifford","year":"2017","unstructured":"Clifford, A. H. et al. Positron emission tomography\/computerized tomography in newly diagnosed patients with giant cell arteritis who are taking glucocorticoids. J. Rheumatol. 44, 1859\u20131866 (2017).","journal-title":"J. Rheumatol."},{"key":"458_CR79","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","volume":"70","author":"PC Grayson","year":"2018","unstructured":"Grayson, P. C. et al. 18 F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 70, 439\u2013449 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"458_CR80","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/art.21699","volume":"55","author":"D Blockmans","year":"2006","unstructured":"Blockmans, D. et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 55, 131\u2013137 (2006).","journal-title":"Arthritis Rheum."},{"key":"458_CR81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2017.08.013","volume":"46","author":"H de Boysson","year":"2017","unstructured":"de Boysson, H. et al. Repetitive 18F-FDG-PET\/CT in patients with large-vessel giant-cell arteritis and controlled disease. Eur. J. Intern. Med. 46, 66\u201370 (2017).","journal-title":"Eur. J. Intern. Med."},{"key":"458_CR82","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.semarthrit.2017.08.009","volume":"47","author":"I Mart\u00ednez-Rodr\u00edguez","year":"2018","unstructured":"Mart\u00ednez-Rodr\u00edguez, I. et al. 18 F-FDG PET\/CT in the follow-up of large-vessel vasculitis: a study of 37 consecutive patients. Semin. Arthritis Rheum. 47, 530\u2013537 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"458_CR83","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/rheumatology\/ken119","volume":"47","author":"D Blockmans","year":"2008","unstructured":"Blockmans, D. et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology 47, 1179\u20131184 (2008).","journal-title":"Rheumatology"},{"key":"458_CR84","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00000478-198106000-00001","volume":"5","author":"CJ Allsop","year":"1981","unstructured":"Allsop, C. J. & Gallagher, P. J. Temporal artery biopsy in giant-cell arteritis. A reappraisal. Am. J. Surg. Pathol. 5, 317\u2013323 (1981).","journal-title":"Am. J. Surg. Pathol."},{"key":"458_CR85","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0950-3579(05)80061-5","volume":"5","author":"M Ashton-Key","year":"1991","unstructured":"Ashton-Key, M. & Gallagher, P. J. Surgical pathology of cranial arteritis and polymyalgia rheumatica. Baillieres Clin. Rheumatol. 5, 387\u2013404 (1991).","journal-title":"Baillieres Clin. Rheumatol."},{"key":"458_CR86","first-page":"69","volume":"1","author":"JT Lie","year":"1996","unstructured":"Lie, J. T. Temporal artery biopsy diagnosis of giant cell arteritis: lessons from 1109 biopsies. Anat. Pathol. 1, 69\u201397 (1996).","journal-title":"Anat. Pathol."},{"key":"458_CR87","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/rheumatology\/ker163","volume":"50","author":"S Visvanathan","year":"2011","unstructured":"Visvanathan, S. et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis \u2014 a prospective longitudinal study. Rheumatology 50, 2061\u20132070 (2011).","journal-title":"Rheumatology"},{"key":"458_CR88","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/modpathol.2017.10","volume":"30","author":"JJ Maleszewski","year":"2017","unstructured":"Maleszewski, J. J. et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod. Pathol. 30, 788\u2013796 (2017).","journal-title":"Mod. Pathol."},{"key":"458_CR89","doi-asserted-by":"crossref","first-page":"845","DOI":"10.7326\/0003-4819-77-6-845","volume":"77","author":"P Fauchald","year":"1972","unstructured":"Fauchald, P., Rygvold, O. & Oystese, B. Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings. Ann. Intern. Med. 77, 845\u2013852 (1972).","journal-title":"Ann. Intern. Med."},{"issue":"Suppl. 9","key":"458_CR90","first-page":"2425","volume":"70","author":"V Sch\u00f6nau","year":"2018","unstructured":"Sch\u00f6nau, V., Roth, J., Englbrecht, M., Rech, J. & Schett, G. Does an 18F-FDG-PET\/CT in patients with giant cell arteritis in clinical remission make sense? [abstract 2200]. Arthritis Rheumatol. 70 (Suppl. 9), 2425\u20132426 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"458_CR91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3899\/jrheum.181222","volume":"47","author":"S Banerjee","year":"2020","unstructured":"Banerjee, S. et al. Effect of treatment on imaging, clinical, and serologic assessments of disease activity in large-vessel vasculitis. J. Rheumatol. 47, 99\u2013107 (2020).","journal-title":"J. Rheumatol."},{"issue":"Suppl. 2","key":"458_CR92","first-page":"A591","volume":"78","author":"V Sch\u00f6nau","year":"2019","unstructured":"Sch\u00f6nau, V. et al. THU0599 resolution of vascular inflammation in patients with giant cell arteritis receiving glucocorticoids, methotrexate or tocilizumab treatment-data from the Italian\/German RIGA study. Ann. Rheum. Dis. 78 (Suppl. 2), A591 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR93","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000486","volume":"94","author":"S Prieto-Gonz\u00e1lez","year":"2015","unstructured":"Prieto-Gonz\u00e1lez, S. et al. Effect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. a prospective, longitudinal study. Medicine 94, e486 (2015).","journal-title":"Medicine"},{"key":"458_CR94","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","volume":"57","author":"S Reichenbach","year":"2018","unstructured":"Reichenbach, S. et al. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology 57, 982\u2013986 (2018).","journal-title":"Rheumatology"},{"key":"458_CR95","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2007.082123","volume":"67","author":"M Both","year":"2008","unstructured":"Both, M. et al. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann. Rheum. Dis. 67, 1030\u20131033 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR96","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/annrheumdis-2018-213102","volume":"77","author":"KA Quinn","year":"2018","unstructured":"Quinn, K. A. et al. Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann. Rheum. Dis. 77, 1165\u20131171 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR97","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s00259-015-3007-8","volume":"42","author":"I Einspieler","year":"2015","unstructured":"Einspieler, I. et al. Imaging large vessel vasculitis with fully integrated PET\/MRI: a pilot study. Eur. J. Nucl. Med. Mol. Imaging 42, 1012\u20131024 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"458_CR98","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48709-w","volume":"9","author":"C Laurent","year":"2019","unstructured":"Laurent, C. et al. PET\/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity. Sci. Rep. 9, 12388 (2019).","journal-title":"Sci. Rep."},{"key":"458_CR99","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","volume":"71","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta, B. et al. Provisional classification criteria for polymyalgia rheumatica: a European league against rheumatism\/American college of rheumatology collaborative initiative. Ann. Rheum. Dis. 71, 484\u2013492 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR100","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/ard.2009.113555","volume":"69","author":"M Jimenez-Palop","year":"2010","unstructured":"Jimenez-Palop, M. et al. Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica. Ann. Rheum. Dis. 69, 879\u2013882 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR101","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kep286","volume":"48","author":"P Macchioni","year":"2009","unstructured":"Macchioni, P., Catanoso, M. G., Pipitone, N., Boiardi, L. & Salvarani, C. Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology 48, 1566\u20131569 (2009).","journal-title":"Rheumatology"},{"key":"458_CR102","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/rheumatology\/keq450","volume":"51","author":"D Camellino","year":"2012","unstructured":"Camellino, D. & Cimmino, M. A. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology 51, 77\u201386 (2012).","journal-title":"Rheumatology"},{"key":"458_CR103","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","volume":"46","author":"D Blockmans","year":"2007","unstructured":"Blockmans, D. et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology 46, 672\u2013677 (2007).","journal-title":"Rheumatology"},{"key":"458_CR104","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00259-015-3287-z","volume":"43","author":"X Palard-Novello","year":"2016","unstructured":"Palard-Novello, X. et al. Value of (18)F-FDG PET\/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. Eur. J. Nucl. Med. Mol. Imaging 43, 773\u2013779 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"458_CR105","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000100","volume":"1","author":"SL Mackie","year":"2015","unstructured":"Mackie, S. L. et al. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open 1, e000100 (2015).","journal-title":"RMD Open"},{"key":"458_CR106","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001003","volume":"5","author":"S Monti","year":"2019","unstructured":"Monti, S. et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open 5, e001003 (2019).","journal-title":"RMD Open"},{"key":"458_CR107","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kez672","volume":"59","author":"SL Mackie","year":"2020","unstructured":"Mackie, S. L. et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology 59, e1\u2013e23 (2020).","journal-title":"Rheumatology"},{"key":"458_CR108","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003210","volume":"95","author":"A Hocevar","year":"2016","unstructured":"Hocevar, A. et al. Do early diagnosis and glucocorticoid treatment decrease the risk of permanent visual loss and early relapses in giant cell arteritis. Medicine 95, e3210 (2016).","journal-title":"Medicine"},{"key":"458_CR109","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003524","volume":"95","author":"G Restuccia","year":"2016","unstructured":"Restuccia, G. et al. Flares in biopsy-proven giant cell arteritis in northern Italy: characteristics and predictors in a long-term follow-up study. Medicine 95, e3524 (2016).","journal-title":"Medicine"},{"issue":"Suppl. 2","key":"458_CR110","first-page":"810","volume":"78","author":"S Unizony","year":"2019","unstructured":"Unizony, S. et al. FRI0261 Risk factors for treatment failure in patients with giant cell arteritis treated with tocilizumab plus prednisone versus prednisone alone. Ann. Rheum. Dis. 78 (Suppl. 2), 810 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR111","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3899\/jrheum.181127","volume":"47","author":"A Dumont","year":"2020","unstructured":"Dumont, A. et al. Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis. J. Rheumatol. 47, 108\u2013116 (2020).","journal-title":"J. Rheumatol."},{"key":"458_CR112","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco, C. et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann. Rheum. Dis. 74, 1799\u20131807 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR113","doi-asserted-by":"crossref","first-page":"1759720X1986482","DOI":"10.1177\/1759720X19864822","volume":"11","author":"K Hayashi","year":"2019","unstructured":"Hayashi, K. et al. Thrombocytosis as a prognostic factor in polymyalgia rheumatica: characteristics determined from cluster analysis. Ther. Adv. Musculoskelet. Dis. 11, 1759720X1986482 (2019).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"458_CR114","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/ken098","volume":"47","author":"MA Cimmino","year":"2008","unstructured":"Cimmino, M. A., Zampogna, G. & Parodi, M. Is FDG-PET useful in the evaluation of steroid-resistant PMR patients? Rheumatology 47, 926\u2013927 (2008).","journal-title":"Rheumatology"},{"key":"458_CR115","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.semarthrit.2018.05.007","volume":"48","author":"D Prieto-Pe\u00f1a","year":"2019","unstructured":"Prieto-Pe\u00f1a, D. et al. Predictors of positive 18F-FDG PET\/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. Semin. Arthritis Rheum. 48, 720\u2013727 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"458_CR116","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3899\/jrheum.160090","volume":"44","author":"MC Miceli","year":"2017","unstructured":"Miceli, M. C. et al. Baseline shoulder ultrasonography is not a predictive marker of response to glucocorticoids in patients with polymyalgia rheumatica: A 12-month followup study. J. Rheumatol. 44, 241\u2013247 (2017).","journal-title":"J. Rheumatol."},{"key":"458_CR117","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich, B. et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 79, 19\u201330 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR118","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","volume":"16","author":"F Buttgereit","year":"2020","unstructured":"Buttgereit, F. Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat. Rev. Rheumatol. 16, 239\u2013246 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"458_CR119","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh, M. et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 54, 3310\u20133318 (2006).","journal-title":"Arthritis Rheum."},{"key":"458_CR120","first-page":"1484","volume":"27","author":"P Chevalet","year":"2000","unstructured":"Chevalet, P. et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J. Rheumatol. 27, 1484\u20131491 (2000).","journal-title":"J. Rheumatol."},{"key":"458_CR121","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3899\/jrheum.110977","volume":"39","author":"EL Matteson","year":"2012","unstructured":"Matteson, E. L. et al. Patient-reported outcomes in polymyalgia rheumatica. J. Rheumatol. 39, 795\u2013803 (2012).","journal-title":"J. Rheumatol."},{"key":"458_CR122","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","volume":"37","author":"B Dasgupta","year":"1998","unstructured":"Dasgupta, B., Dolan, A. L., Panayi, G. S. & Fernandes, L. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Rheumatology 37, 189\u2013195 (1998).","journal-title":"Rheumatology"},{"key":"458_CR123","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr, A. D. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56, 2789\u20132797 (2007).","journal-title":"Arthritis Rheum."},{"key":"458_CR124","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco, C. et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism\/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann. Rheum. Dis. 74, 1808\u20131817 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali, R. et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 141, 493\u2013500 (2004).","journal-title":"Ann. Intern. Med."},{"key":"458_CR126","first-page":"395","volume":"26","author":"MA Cimmino","year":"2008","unstructured":"Cimmino, M. A. et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin. Exp. Rheumatol. 26, 395\u2013400 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"key":"458_CR127","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3899\/jrheum.150599","volume":"43","author":"\u00c9 Toussirot","year":"2016","unstructured":"Toussirot, \u00c9., Martin, A., Soubrier, M., Redeker, S. & R\u00e9gent, A. Rapid and sustained response to tocilizumab in patients with polymyalgia rheumatica resistant or intolerant to glucocorticoids: a multicenter open-label study. J. Rheumatol. 43, 249\u2013250 (2016).","journal-title":"J. Rheumatol."},{"key":"458_CR128","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00296-018-4086-1","volume":"38","author":"D Camellino","year":"2018","unstructured":"Camellino, D., Soldano, S., Cutolo, M. & Cimmino, M. A. Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition. Rheumatol. Int. 38, 1699\u20131704 (2018).","journal-title":"Rheumatol. Int."},{"key":"458_CR129","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/1756-185X.13723","volume":"22","author":"K Chino","year":"2019","unstructured":"Chino, K. et al. Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study. Int. J. Rheum. Dis. 22, 2151\u20132157 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"458_CR130","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03600818 (2020)."},{"key":"458_CR131","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","volume":"38","author":"K Albrecht","year":"2018","unstructured":"Albrecht, K. et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol. Int. 38, 569\u2013577 (2018).","journal-title":"Rheumatol. Int."},{"key":"458_CR132","first-page":"S98","volume":"33","author":"A Chandran","year":"2015","unstructured":"Chandran, A. et al. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin. Exp. Rheumatol. 33, S98\u2013S102 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"458_CR133","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.23901","volume":"72","author":"S Mainbourg","year":"2019","unstructured":"Mainbourg, S. et al. Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis. Arthritis Care Res. 72, 838\u2013849 (2019).","journal-title":"Arthritis Care Res."},{"key":"458_CR134","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger, P. M. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387, 1921\u20131927 (2016).","journal-title":"Lancet"},{"key":"458_CR135","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","volume":"58","author":"S Adler","year":"2019","unstructured":"Adler, S. et al. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology 58, 1639\u20131643 (2019).","journal-title":"Rheumatology"},{"key":"458_CR136","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/acr.23320","volume":"70","author":"I Shbeeb","year":"2018","unstructured":"Shbeeb, I., Challah, D., Raheel, S., Crowson, C. S. & Matteson, E. L. Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population. Arthritis Care Res. 70, 643\u2013647 (2018).","journal-title":"Arthritis Care Res."},{"key":"458_CR137","first-page":"S86","volume":"31","author":"F Muratore","year":"2013","unstructured":"Muratore, F., Pipitone, N., Hunder, G. G. & Salvarani, C. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clin. Exp. Rheumatol. 31, S86\u2013S92 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"458_CR138","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa011","author":"SW Borresen","year":"2020","unstructured":"Borresen, S. W. et al. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keaa011 (2020).","journal-title":"Rheumatology"},{"key":"458_CR139","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.rdc.2019.07.005","volume":"45","author":"D Camellino","year":"2019","unstructured":"Camellino, D., Dejaco, C., Buttgereit, F. & Matteson, E. L. Treat to target: a valid concept for management of polymyalgia rheumatica and giant cell arteritis? Rheum. Dis. Clin. North Am. 45, 549\u2013567 (2019).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"458_CR140","doi-asserted-by":"crossref","first-page":"E680","DOI":"10.1503\/cmaj.190178","volume":"191","author":"J Wu","year":"2019","unstructured":"Wu, J., Keeley, A., Mallen, C., Morgan, A. W. & Pujades-Rodriguez, M. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ 191, E680\u2013E688 (2019).","journal-title":"CMAJ"},{"key":"458_CR141","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl, C. et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann. Rheum. Dis. 75, 952\u2013957 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR142","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au, K. et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 785\u2013791 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR143","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41927-019-0094-3","volume":"3","author":"CT Ritchlin","year":"2019","unstructured":"Ritchlin, C. T. et al. Serious infections in patients with self-reported psoriatic arthritis from the psoriasis longitudinal assessment and registry (PSOLAR) treated with biologics. BMC Rheumatol. 3, 52 (2019).","journal-title":"BMC Rheumatol."},{"key":"458_CR144","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0961203313493032","volume":"22","author":"A Danza","year":"2013","unstructured":"Danza, A. & Ruiz-Irastorza, G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 22, 1286\u20131294 (2013).","journal-title":"Lupus"},{"key":"458_CR145","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0961203319860579","volume":"28","author":"VR Pimentel-Quiroz","year":"2019","unstructured":"Pimentel-Quiroz, V. R. et al. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus 28, 1101\u20131110 (2019).","journal-title":"Lupus"},{"key":"458_CR146","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s10067-018-4067-5","volume":"37","author":"J Yoo","year":"2018","unstructured":"Yoo, J., Jung, S. M., Song, J. J., Park, Y.-B. & Lee, S.-W. Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis. Clin. Rheumatol. 37, 2133\u20132141 (2018).","journal-title":"Clin. Rheumatol."},{"key":"458_CR147","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3899\/jrheum.190065","volume":"47","author":"E Garcia-Vives","year":"2020","unstructured":"Garcia-Vives, E., Segarra-Medrano, A., Martinez-Valle, F., Agraz, I. & Solans-Laque, R. Prevalence and risk factors for major infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis: influence on the disease outcome. J. Rheumatol. 47, 407\u2013414 (2020).","journal-title":"J. Rheumatol."},{"key":"458_CR148","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"Duru, N. et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 72, 1905\u20131913 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR149","volume":"4","author":"LYH Lai","year":"2018","unstructured":"Lai, L. Y. H., Harris, E., West, R. M. & Mackie, S. L. Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis. RMD Open 4, e000521 (2018).","journal-title":"RMD Open"},{"key":"458_CR150","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","volume":"76","author":"EM Miloslavsky","year":"2017","unstructured":"Miloslavsky, E. M. et al. Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis. Ann. Rheum. Dis. 76, 543\u2013546 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR151","first-page":"311","volume":"13","author":"EE Sproul","year":"1937","unstructured":"Sproul, E. E. & Hawthorne, J. J. Chronic diffuse mesaortitis: report of two cases of unusual type. Am. J. Pathol. 13, 311\u2013323.4 (1937).","journal-title":"Am. J. Pathol."},{"key":"458_CR152","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jcp.1.4.197","volume":"1","author":"CV Harrison","year":"1948","unstructured":"Harrison, C. V. Giant-cell or temporal arteritis: a review. J. Clin. Pathol. 1, 197\u2013211 (1948).","journal-title":"J. Clin. Pathol."},{"key":"458_CR153","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/hrt.30.6.840","volume":"30","author":"M Harris","year":"1968","unstructured":"Harris, M. Dissecting aneurysm of the aorta due to giant cell arteritis. Br. Heart J. 30, 840\u2013844 (1968).","journal-title":"Br. Heart J."},{"key":"458_CR154","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/annrheumdis-2012-202408","volume":"72","author":"TA Kermani","year":"2013","unstructured":"Kermani, T. A. et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann. Rheum. Dis. 72, 1989\u20131994 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR155","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.11353","volume":"48","author":"DM Nuenninghoff","year":"2003","unstructured":"Nuenninghoff, D. M., Hunder, G. G., Christianson, T. J. H., McClelland, R. L. & Matteson, E. L. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 48, 3522\u20133531 (2003).","journal-title":"Arthritis Rheum."},{"key":"458_CR156","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2012-202145","volume":"73","author":"SL Mackie","year":"2014","unstructured":"Mackie, S. L., Hensor, E. M. A., Morgan, A. W. & Pease, C. T. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann. Rheum. Dis. 73, 143\u2013148 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR157","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1161\/CIRCULATIONAHA.106.630400","volume":"114","author":"C Olsson","year":"2006","unstructured":"Olsson, C., Thelin, S., Sta\u030ahle, E., Ekbom, A. & Granath, F. Thoracic aortic aneurysm and dissection. Circulation 114, 2611\u20132618 (2006).","journal-title":"Circulation"},{"key":"458_CR158","first-page":"S94","volume":"31","author":"MA Gonzalez-Gay","year":"2013","unstructured":"Gonzalez-Gay, M. A. et al. Biopsy-proven giant cell arteritis patients with coronary artery disease have increased risk of aortic aneurysmal disease and arterial thrombosis. Clin. Exp. Rheumatol. 31, S94 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"458_CR159","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/annrheumdis-2013-204113","volume":"74","author":"JC Robson","year":"2015","unstructured":"Robson, J. C. et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann. Rheum. Dis. 74, 129\u2013135 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR160","volume":"95","author":"H de Boysson","year":"2016","unstructured":"de Boysson, H. et al. 18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis. A multicenter cohort of 130 patients. Medicine 95, e3851 (2016).","journal-title":"Medicine"},{"key":"458_CR161","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.autrev.2017.11.029","volume":"17","author":"H de Boysson","year":"2018","unstructured":"de Boysson, H. et al. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. Autoimmun. Rev. 17, 391\u2013398 (2018).","journal-title":"Autoimmun. Rev."},{"key":"458_CR162","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","volume":"122","author":"JM Evans","year":"1995","unstructured":"Evans, J. M., O\u2019Fallon, W. M. & Hunder, G. G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann. Intern. Med. 122, 502\u2013507 (1995).","journal-title":"Ann. Intern. Med."},{"key":"458_CR163","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/RHU.0000000000000381","volume":"22","author":"TA Kermani","year":"2016","unstructured":"Kermani, T. A. et al. Predictors of dissection in aortic aneurysms from giant cell arteritis. J. Clin. Rheumatol. 22, 184\u2013187 (2016).","journal-title":"J. Clin. Rheumatol."},{"key":"458_CR164","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.revmed.2015.12.015","volume":"37","author":"B Bienvenu","year":"2016","unstructured":"Bienvenu, B. et al. Management of giant cell arteritis: recommendations of the French study group for large vessel vasculitis (GEFA). Rev. Med. Interne 37, 154\u2013165 (2016).","journal-title":"Rev. Med. Interne"},{"issue":"Suppl. 9","key":"458_CR165","first-page":"897","volume":"70","author":"N Marin Zucaro","year":"2018","unstructured":"Marin Zucaro, N. et al. Development of thoracic aortic aneurysms in patients with polymyalgia rheumatica: underdiagnosed giant cell arteritis? [abstract 816]. Arthritis Rheumatol. 70 (Suppl. 9), 897\u2013898 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"458_CR166","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/M12-3046","volume":"160","author":"G Tomasson","year":"2014","unstructured":"Tomasson, G. et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann. Intern. Med. 160, 73\u201380 (2014).","journal-title":"Ann. Intern. Med."},{"key":"458_CR167","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3899\/jrheum.151024","volume":"43","author":"JC Robson","year":"2016","unstructured":"Robson, J. C. et al. Which patients with giant cell arteritis will develop cardiovascular or cerebrovascular disease? A clinical practice research datalink study. J. Rheumatol. 43, 1085\u20131092 (2016).","journal-title":"J. Rheumatol."},{"key":"458_CR168","first-page":"753","volume":"56","author":"L Li","year":"2017","unstructured":"Li, L., Neogi, T. & Jick, S. Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK clinical practice research datalink. Rheumatology 56, 753\u2013762 (2017).","journal-title":"Rheumatology"},{"key":"458_CR169","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","volume":"50","author":"G Nesher","year":"2004","unstructured":"Nesher, G. et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 50, 1332\u20131337 (2004).","journal-title":"Arthritis Rheum."},{"key":"458_CR170","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.22141","volume":"54","author":"MS Lee","year":"2006","unstructured":"Lee, M. S., Smith, S. D., Galor, A. & Hoffman, G. S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 54, 3306\u20133309 (2006).","journal-title":"Arthritis Rheum."},{"key":"458_CR171","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00296-016-3557-5","volume":"37","author":"P Ungprasert","year":"2017","unstructured":"Ungprasert, P., Koster, M. J., Warrington, K. J. & Matteson, E. L. Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies. Rheumatol. Int. 37, 143\u2013149 (2017).","journal-title":"Rheumatol. Int."},{"key":"458_CR172","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/acr.21712","volume":"64","author":"AT Hancock","year":"2012","unstructured":"Hancock, A. T., Mallen, C. D., Belcher, J. & Hider, S. L. Association between polymyalgia rheumatica and vascular disease: a systematic review. Arthritis Care Res. 64, 1301\u20131305 (2012).","journal-title":"Arthritis Care Res."},{"key":"458_CR173","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/heartjnl-2015-308514","volume":"102","author":"M Pujades-Rodriguez","year":"2016","unstructured":"Pujades-Rodriguez, M. et al. Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. Heart 102, 383\u2013389 (2016).","journal-title":"Heart"},{"key":"458_CR174","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/1756-185X.13328","volume":"21","author":"D Kobayashi","year":"2018","unstructured":"Kobayashi, D. et al. Incidence of cardiovascular events in polymyalgia rheumatica and giant cell arteritis amongst an Asian population: propensity score matched cohort study. Int. J. Rheum. Dis. 21, 1314\u20131321 (2018).","journal-title":"Int. J. Rheum. Dis."},{"key":"458_CR175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0002-9343(97)89458-2","volume":"100","author":"EL Matteson","year":"1996","unstructured":"Matteson, E. L., Gold, K. N., Bloch, D. A. & Hunder, G. G. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am. J. Med. 100, 193\u2013196 (1996).","journal-title":"Am. J. Med."},{"key":"458_CR176","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2016.08.015","volume":"46","author":"CL Hill","year":"2017","unstructured":"Hill, C. L. et al. Risk of mortality in patients with giant cell arteritis: a systematic review and meta-analysis. Semin. Arthritis Rheum. 46, 513\u2013519 (2017).","journal-title":"Semin. Arthritis Rheum."},{"key":"458_CR177","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13075-019-1945-4","volume":"21","author":"LK Brekke","year":"2019","unstructured":"Brekke, L. K. et al. Survival and death causes of patients with giant cell arteritis in Western Norway 1972\u20132012: a retrospective cohort study. Arthritis Res. Ther. 21, 154 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"458_CR178","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","volume":"69","author":"S Raheel","year":"2017","unstructured":"Raheel, S., Shbeeb, I., Crowson, C. S. & Matteson, E. L. Epidemiology of polymyalgia rheumatica 2000\u20132014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res. 69, 1282\u20131285 (2017).","journal-title":"Arthritis Care Res."},{"key":"458_CR179","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford, C. A. et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 69, 837\u2013845 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"458_CR180","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03600805 (2020)."},{"key":"458_CR181","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03725202 (2020)."},{"key":"458_CR182","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03026504 (2020)."},{"key":"458_CR183","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03827018 (2020)."},{"key":"458_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03765788 (2020)."},{"key":"458_CR185","first-page":"S102","volume":"35","author":"L Pulsatelli","year":"2017","unstructured":"Pulsatelli, L. et al. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin. Exp. Rheumatol. 35, S102\u2013S110 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"458_CR186","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2018-214704","volume":"78","author":"CT Berger","year":"2019","unstructured":"Berger, C. T., Rebholz-Chaves, B., Recher, M., Manigold, T. & Daikeler, T. Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. Ann. Rheum. Dis. 78, 1012\u20131014 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR187","volume":"79","author":"M Samson","year":"2019","unstructured":"Samson, M. & Bonnotte, B. Analysis of IL-6 measurement in patients with GCA treated with tocilizumab should consider concomitant treatment with prednisone. Ann. Rheum. Dis. 79, e102 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"458_CR188","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/keu526","volume":"54","author":"KSM van der Geest","year":"2015","unstructured":"van der Geest, K. S. M. et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology 54, 1397\u20131402 (2015).","journal-title":"Rheumatology"},{"key":"458_CR189","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.23924","volume":"59","author":"L Pulsatelli","year":"2008","unstructured":"Pulsatelli, L. et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse\/recurrence risk. Arthritis Rheum. 59, 1147\u20131154 (2008).","journal-title":"Arthritis Rheum."},{"key":"458_CR190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/03009740410009931","volume":"34","author":"JG Brun","year":"2005","unstructured":"Brun, J. G., Madland, T. M., Gran, J. T. & Myklebust, G. A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity. Scand. J. Rheumatol. 34, 125\u2013128 (2005).","journal-title":"Scand. J. Rheumatol."},{"key":"458_CR191","doi-asserted-by":"crossref","first-page":"rkz018","DOI":"10.1093\/rap\/rkz018","volume":"3","author":"JKM Sundholm","year":"2019","unstructured":"Sundholm, J. K. M., Pettersson, T., Paetau, A., Alb\u00e4ck, A. & Sarkola, T. Diagnostic performance and utility of very high-resolution ultrasonography in diagnosing giant cell arteritis of the temporal artery. Rheumatol. Adv. Pract. 3, rkz018 (2019).","journal-title":"Rheumatol. Adv. Pract."}],"updated-by":[{"DOI":"10.1038\/s41584-020-00505-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000}}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0458-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T23:37:41Z","timestamp":1628120261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0458-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":191,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-0458-5","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41584-020-00505-x","asserted-by":"object"}]},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"18 June 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.C. has received consultancy and speaker fees from AbbVie, Celgene, Janssen-Cilag, Lilly, Mylan, Novartis and Sanofi. E.L.M. was a site investigator for the GiACTA study and is a contributor and section editor for UpToDate. F.B. has received consultancy and speaker fees as well as research grants from Mundipharma, Horizon and Roche\/Chugai. C.D. has received consultancy and speaker fees from AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi and UCB, and a research grant from Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}